Nazzi Gianfranco 4
4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 8, 2021
Insider Transaction Report
Form 4
Nazzi Gianfranco
EVP, Growth Markets Commercial
Transactions
- Exercise/Conversion
Restricted Share Units
2021-03-04−12,935→ 25,870 total→ Ordinary Shares (12,935 underlying) - Award
Ordinary Shares
2021-03-04+12,935→ 12,935 total - Sale
Ordinary Shares
2021-03-04$10.58/sh−12,935$136,909→ 0 total
Footnotes (5)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.510 to $10.700, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F5]Restricted share units were granted on March 4, 2019, with 12,935 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023.